Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

PURPOSE: A phase I trial of veliparib in combination with topotecan plus carboplatin (T+C) demonstrated 33% objective response rate in patients with hematological malignancies. The objective is to perform exposure-response analysis to inform the phase II trial design. EXPERIMENTAL DESIGN: Pharmacoki...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Mehrotra, Shailly, Gopalakrishnan, Mathangi, Gobburu, Jogarao, Ji, Jiuping, Greer, Jacqueline M., Piekarz, Richard, Karp, Judith E., Pratz, Keith W., Rudek, Michelle A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5837045/
https://ncbi.nlm.nih.gov/pubmed/28751440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0143
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados